- Home
- TEAF vs VIGL Comparison
TEAF vs VIGL Comparison
Compare TEAF & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- VIGL
- Stock Information
- Founded
- TEAF 2017
- VIGL 2020
- Country
- TEAF United States
- VIGL United States
- Employees
- TEAF N/A
- VIGL N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- VIGL Health Care
- Exchange
- TEAF Nasdaq
- VIGL Nasdaq
- Market Cap
- TEAF 165.2M
- VIGL 148.7M
- IPO Year
- TEAF N/A
- VIGL 2022
- Fundamental
- Price
- TEAF $12.83
- VIGL $3.48
- Analyst Decision
- TEAF
- VIGL Buy
- Analyst Count
- TEAF 0
- VIGL 5
- Target Price
- TEAF N/A
- VIGL $16.60
- AVG Volume (30 Days)
- TEAF 56.1K
- VIGL 79.9K
- Earning Date
- TEAF 01-01-0001
- VIGL 11-05-2024
- Dividend Yield
- TEAF 9.20%
- VIGL N/A
- EPS Growth
- TEAF N/A
- VIGL N/A
- EPS
- TEAF N/A
- VIGL N/A
- Revenue
- TEAF N/A
- VIGL N/A
- Revenue This Year
- TEAF N/A
- VIGL N/A
- Revenue Next Year
- TEAF N/A
- VIGL N/A
- P/E Ratio
- TEAF N/A
- VIGL N/A
- Revenue Growth
- TEAF N/A
- VIGL N/A
- 52 Week Low
- TEAF $11.11
- VIGL $2.47
- 52 Week High
- TEAF $13.30
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- TEAF 66.90
- VIGL 46.82
- Support Level
- TEAF $12.67
- VIGL $3.46
- Resistance Level
- TEAF $13.00
- VIGL $3.83
- Average True Range (ATR)
- TEAF 0.12
- VIGL 0.29
- MACD
- TEAF 0.03
- VIGL 0.00
- Stochastic Oscillator
- TEAF 79.39
- VIGL 34.98
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.